Marshall Wace
CGEM icon

Marshall Wace’s Cullinan Oncology CGEM Stock Holding History

Marshall Wace’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.2M Sell
66,051
-983,530
-94% -$14.6M ﹤0.01% 2104
2026
Q1 		$14.9M Buy
1,049,581
+635,222
+153% +$8.16M 0.01% 807
2025
Q4 		$4.29M Buy
414,359
+118,917
+40% +$1.07M ﹤0.01% 1222
2025
Q3 		$1.75M Sell
295,442
-331,139
-53% -$2.43M ﹤0.01% 1681
2025
Q2 		$4.72M Buy
626,581
+58,582
+10% +$471K 0.01% 1162
2025
Q1 		$4.3M Sell
567,999
-83,694
-13% -$803K 0.01% 1136
2024
Q4 		$7.94M Sell
651,693
-402,071
-38% -$5.78M 0.01% 882
2024
Q3 		$17.6M Sell
1,053,764
-130,273
-11% -$2.31M 0.02% 551
2024
Q2 		$20.6M Buy
1,184,037
+1,136,993
+2,417% +$24.2M 0.03% 491
2024
Q1 		$802K Buy
47,044
+13,670
+41% +$211K ﹤0.01% 1742
2023
Q4 		$340K Buy
+33,374
New +$296K ﹤0.01% 1851
2023
Q3 		– Sell
-10,837
Closed -$117K – 2241
2023
Q2 		$117K Buy
+10,837
New +$115K ﹤0.01% 2310
2022
Q4 		– Sell
-40,576
Closed -$520K – 2974
2022
Q3 		$520K Sell
40,576
-2,547
-6% -$34.3K ﹤0.01% 2706
2022
Q2 		$553K Buy
+43,123
New +$489K ﹤0.01% 2744
2021
Q3 		– Sell
-74,951
Closed -$1.93M – 3057
2021
Q2 		$1.93M Buy
+74,951
New +$2.3M 0.01% 1461

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Marshall Wace's CGEM Position: Q2 2026 in Review

Marshall Wace reduced its Cullinan Oncology (CGEM) stake by 94% in Q2 2026, selling an estimated $14.6M and leaving 66,051 shares worth $1.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2104.

Marshall Wace first reported a position in CGEM in Q2 2021 and has held it in 15 quarters since. The position peaked at $20.6M in Q2 2024. 184 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Marshall Wace held 66,051 shares of Cullinan Oncology worth $1.2M as of Q2 2026.
  • Marshall Wace sold 983,530 Cullinan Oncology shares in Q2 2026, an estimated $14.6M.
  • Cullinan Oncology made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2104 holding.
  • Marshall Wace first reported a position in Cullinan Oncology in Q2 2021 and has held it in 15 quarters since.
  • Marshall Wace's Cullinan Oncology position peaked at $20.6M in Q2 2024.
  • 184 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.